{"schema_version":"secwatch.filing_event.v1","accession":"0001082554-24-000037","form_type":"8-K","ticker":"UTHR","cik":"0001082554","company_name":"UNITED THERAPEUTICS Corp","filed_at":"2024-07-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.116077+00:00","generated_at":"2026-05-31T14:14:51.411312+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"United Therapeutics Q2 2024 revenue up 20% to $714.9M, EPS $5.85","bullets":["Total revenues $714.9M (+20% YoY); net income $278.1M ($5.85 diluted EPS) vs $259.2M ($5.24) in Q2 2023.","Tyvaso products revenue $398.2M (+25% YoY), led by Tyvaso DPI growth from PH-ILD launch.","Remodulin $147.3M (+16%), Orenitram $107.1M (+13%), Unituxin $51.7M (+17%).","R&D expense rose 57% to $139.6M, driven by upfront licensing payments and organ manufacturing.","Completed $300M tranche of $1B ASR; final $700M settlement expected in Q3 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001082554-24-000037","json":"https://secwatch.observer/filing/0001082554-24-000037.json","markdown":"https://secwatch.observer/filing/0001082554-24-000037.md","text":"https://secwatch.observer/filing/0001082554-24-000037.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1082554/000108255424000037/0001082554-24-000037-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1082554/000108255424000037/uthr-20240731.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T14:14:51.411312+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}